MedTrace Logo

Italian Anderson Fabry Disease Cardiovascular Registry

NCT06806813 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2025-02-04

No results posted yet for this study

Summary

The RICMAF Study is an observational, multicenter, non-pharmacological study conducted in Italy.

Although Anderson-Fabry Disease (AFD) is rare, it is likely underdiagnosed due to its nonspecific symptoms, leading to delays in proper treatment. The RICMAF Study aims to improve understanding of AFD, especially its cardiac manifestations, which are a major cause of mortality. By gathering data from a large, nationwide patient registry, this study seeks to answer key questions about AFD's clinical course and improve patient outcomes.

The primary goals of the RICMAF Study are:

* To analyze the clinical profile, prevalence, and incidence of AFD, along with patients' family history and disease progression.
* To identify early markers of cardiac involvement and predictors of cardiovascular complications to personalize care.
* To investigate the relationship between genetic mutations, clinical presentation, and prognosis.
* To find early indicators of organ damage through laboratory and imaging tests.

All patients diagnosed with AFD following international guidelines are eligible.

Conditions

Sponsors & Collaborators

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    lead OTHER

Principal Investigators

  • Elena Biagini, MD, PhD · IRCCS Azienda Ospedaliero-Universitaria di Bologna

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-26
Primary Completion
2031-01-31
Completion
2031-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06806813 on ClinicalTrials.gov